Allergic Diseases
11
3
7
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (11)
Guangzhou Preterm and Term Birth Cohort Study
Systems Biology of Early Atopy
Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
Dietary Intervention on Atopy
A Study of Single Dose of LP-003 in Adolescent Subjects
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and/or Mast Cell Disorders
Vitamin D Intervention in Infants - 6 Years Follow-up (VIDI2)
Oral Probiotics to Allergic Pregnant Mother and Their Offspring to Prevent Allergic Disease